|
Metabolic Pharmaceuticals Ltd - Company Profile Snapshot
| Company Profile: |
Metabolic Pharmaceuticals Ltd |
| Ticker: |
MBP |
| Exchanges: |
SYD |
| 2009 Sales: |
n/a |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
AUSTRALIA |
| Employees: |
17 |
Business Description
Metabolic Pharmaceuticals Ltd. The Company's principal activities are developing platforms for the oral delivery of injectable peptide drugs and focusing on taking drug candidates through research, formal preclinical and clinical development. The company's lead project is Oral Peptide Delivery Platform, which develops oral versions of injectable peptide drugs with enhanced absorption. It also plans to prioritize this project to become an important source of in-house development of new drugs. Other projects such as the Obesity Project, and Neuropathic Pain Project, which were developing the drugs AOD9604 and ACV1 respectively, had been discontinued due to lack of evidence of efficacy. The Company is also developing AOD9604 for the potential prevention and / or treatment of osteoporosis. It operates in Australia.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
